Merck Sharp + Dohme Corp.

Bayer Healthcare LLC

Janssen Biotech, Inc.

Merck Sharpe & Dohme Corp.

Timothy McCabe

Rose M Cubbon

Jon H Condra

Ayesha Sitlani

Shilpa Pandit

Yan Li

Pingyu Zhong

Feng Dong

Holly A Hammond

Kevin Caili Wang

Jeffrey T Blue

Laurence B Peterson

Denise K Nawrocki

Joseph C Santoro

Henryk Mach

Sonia M Gregory

Dana D Wood

John Lee

William Strohl

Paul P Tamburini

Michael Naso

Peter Peizhi Luo

Jill Marie Mooney

Heidi Pixley

Lila Adnane

Yan Ni

Sha Ha

Peizhi (Peter) Luo

Heidi Yoder

Gerald Ranges

Dale Lewis

Xun Shen

Chen Ni Chin

Sharon Lobo

Pamela Trail

BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.

Chimeric antigen receptors comprising BCMA-specific fibronectin type III domains and uses thereof

Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

1B20 PCSK9 antagonists

Methods of using PCSK9 antagonists More specifically, methods for measuring circulating PCSK9 levels in a biological sample by means of an immunoassay The immunoassay used can be a solid phase immunoassay, such as a dissociation-enhanced lanthanide fluorescence immunoassay utilizing an E07 capture antibody or coating and a G08 or H23 detecting antibody.

PCSK9 immunoassay

The invention provides antibodies having an antigenic binding site specifically directed against an MN protein, and methods for using such antibodies in treating and diagnosing an MN-related disorder.

Anti-MN antibodies and methods of using same

Growing community of inventors

Doylestown, PA, United States of America

Timothy McCabe